Risk of Dementia in Patients with Diabetes Using Sodium-Glucose Transporter 2 Inhibitors (SGLT2i): A Systematic Review, Meta-Analysis, and Meta-Regression.
Pricilla Yani GunawanPaskalis Andrew GunawanTimotius Ivan HariyantoPublished in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2024)
According to this research, taking SGLT2i reduces the incidence of dementia in people with diabetes by having a beneficial neuroprotective impact. Randomized controlled trials (RCTs) are still required in order to verify the findings of our research.